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THE CORONAVIRUS DISEASE 2019
PANDEMIC AND ESKD

The ﬁrst reported death in the United
States from COVID-19 on February 29,
2020 was a patient receiving maintenance
dialysis. Since then, COVID-19 has
affected all patients receiving maintenance dialysis in this country, by direct
illness or changes to the system.1 Patients
with ESKD have four-fold higher exposure to SARS-CoV-2 than the general
population2 and 3-4X more infections,
but severe illness, deﬁned by need for
hospitalization, is up to 10X higher and
mortality from COVID-19 is 20%–30%
higher. Mortality rates in patients with
ESKD in the US rose by 15%–20% in
20203 compared with similar periods in
2017 through 2019. Mortality from
COVID-19 was also high in patients with
functioning kidney transplants (16% of
deaths in 2020), a 20% increase in mortality from 2018 and 2019.4

SHARING: INFORMATION,
SUPPLIES, AND CAMARADERIE

On March 4, 2020, ASN invited chief
medical ofﬁcers (CMOs) to a conference
call. Fourteen dialysis organizations, caring for .97% of patients with ESKD in
the US, joined the call. After outlining the
status of COVID-19, discussions centered
on emerging data from other countries
suggesting an impending pandemic and
steps providers might take to reduce its
effect on their patients and staff. Medical
ofﬁcers from the CDC shared the latest
available information.
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CMOs recognized the need to bolster
infection prevention protocols5 and a
shared common purpose: to advance
patient-centered care. CMOs understood the need to support the pandemic
response and care for patients in their
medical homes reducing the burden on
hospital systems. CMOs universally
agreed that our vulnerable population
would be best served by continued
collaboration.
Initial hesitation about revealing proprietary information quickly ended and
unpublished data were shared openly.
Early in the pandemic, critical shortages of
personal protective equipment (PPE) created concerns about the feasibility of universal masking in dialysis facilities. CDC
and state surveyors questioned its necessity, but unpublished data indicated beneﬁts.6 The leaders of dialysis organizations
shared resources to help all patients
receive care in the safest possible environment. The burgeoning pandemic required
development of practices to meet its challenges. Before the pandemic, patients often
ate during dialysis; the pandemic limited
this practice.

COLLABORATION AND
INFORMATION SHARING
SAVES LIVES

Proactive screening of patients and staff
entering the dialysis facility reduced exposure to SARS-CoV-2. Our collaboration
led to the Dialysis Community Response
Network, facilities treating patients with
COVID-19 regardless of their home unit
or organization. Care in these facilities

was limited by inability to transport
patients across geographic boundaries
and insufﬁcient capacity so existing facilities dedicated sections for patients with
known or suspected infections, or aggregated patients during the last treatment
shift of the day to facilitate terminal
cleaning.
Early discussions documented the
beneﬁts of home dialysis for reducing
exposure. Expansion of home programs
was limited by inadequate numbers of
staff to train patients. Precise analysis
of the effect of the pandemic on home
dialysis was confounded by the mandatory ESRD Treatment Choices model
implemented during the pandemic. To
limit exposure, some considered shortened dialysis treatments or altered
treatment regimens; however, this was
not recommended or performed on a
large scale.
Controversies addressed by the
group included which clinical scenarios
caused aerosolization and required use
of N-95 masks, goggles, and face shields
as opposed to standard masks. Initially,
information from federal and state
agencies was disparate. By sharing
internal information, emerging data
and expert opinion, the CMOs found
common ground and a uniﬁed
response to surveyors. Elective
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procedures were deferred across the
country early in the pandemic; CMOs
collaborated to encourage CMS to
deﬁne vascular access procedures as
nonelective.
Complex issues included management of staff, who were limited from
socializing with colleagues and traveling despite the risks they undertook in
caring for patients with known and
unknown exposure risks. Guidance
from the CDC and other authorities
required staff traveling to regions with
high rates of SARS-CoV-2 transmission
to isolate before returning to work,
resulting in less time with family. Recognizing their extraordinary importance to the pandemic response, CMOs
shared ideas and practices for supporting and encouraging staff.
Patient-related issues remained central to discussions. Some patients
required dialysis immediately after travel;
sharing protocols for managing these situations helped reduce risk. Patients
residing in group settings required
increased attention. Some patients were
unable to wear masks during treatment
due to comorbid medical conditions,
whereas others simply refused. Sharing
approaches to managing these patients
optimized care.
Working together, the CMOs voiced
the need for prevention and treatment
of COVID-19 in patients with ESKD.
Many therapeutic trials excluded
patients with advanced kidney disease;
through sharing protocols and outcomes, the dialysis community rapidly
gained conﬁdence in their safety and
efﬁcacy, allowing provision of these
medications in dialysis facilities.
Once vaccines became available,
patients with CKD were in priority
group 1c of the ACIP guidelines.7 Recognizing the risks to patients with ESKD,
especially those anticipating transplants,
CMOs expressed urgency about vaccinating patients in their dialysis facilities.
Several states and localities provided vaccines to dialysis providers; most patients
were not so fortunate. The CMOs shared
information regarding timing of vaccine
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administration, vaccine safety and efﬁcacy and management of vaccine hesitancy, facilitating vaccination of nearly
75% of our patients. Dialysis providers,
the CDC, and ASN developed the framework of a network administrator model
for vaccine distribution to dialysis centers across all 50 states, territories, and
tribal nations in rural and urban settings.
The CMOs and the nonphysician leadership of their organizations addressed
our concerns with the CDC, congressional
representatives, governors, and The White
House. In response to this persistent
advocacy, The White House announced
an allocation of vaccines to dialysis providers on March 31, 2021; DaVita and
Fresenius served as distribution hubs for
other providers. Once vaccines became
widely available, some providers mandated employee vaccination. Others hesitated due to worsening shortages in the
health care workforce. Open sharing of
the response to mandates allowed organizations to optimize their respective staff
safety protocols.
Our pooled data from 487,787
patients with ESKD shows an increase in
the proportion of patients completing a
primary series of an approved vaccine
against COVID-19. Notably, the
increases were greater for patients from
minority populations, narrowing initial
disparities (Table 1).

SHARING PROTOCOLS TO
SAFEGUARD EVERYONE

Following CDC’s advice, providers
adapted enhanced cleaning and disinfection protocols, increased separation of
dialysis stations, chairs in waiting areas,

and staff breaks; and asked patients to
wait outside facilities.
The CDC initially had insufﬁcient
information to provide guidance on
cohorting patients with active COVID-19,
managing exposed patients who felt well,
and duration of isolation after clinical
recovery. Prepublication data from CMOs
that patients with ESKD had prolonged
positive SARS-CoV-2 RT-PCR tests compared with fully immunocompetent
patients. Providers and the CDC questioned whether such tests represented risk
of transmission. By sharing data, patterns
emerged allowing CMOs to conclude that
patients who were clinically well could
return to the general treatment population
10–14 days after symptom resolution,
despite positive RT-PCR.8
Rapid adoption of waivers from HHS
allowed telemedicine visits, which
reduced the number of providers in the
dialysis facilities, permitted communication with patients dialyzing at home, and
reduced crowding at hemodialysis centers. Other topics discussed included
permitting visitors in treatment areas
and accepting transient patients from
other dialysis facilities. These common
practices ended in most facilities at the
onset of the pandemic. For patients
requiring assistance during dialysis treatments shared protocols facilitated the
safe inclusion of visitors.9
Hot spots early in the pandemic
faced supply shortages of solutions for
acute dialysis treatments. Approaches
to management of AKI including
reducing dialysate ﬂow rates, novel
approaches to CKRT, onsite manufacturing of ﬂuids, and treatment of
AKI by PD allowed all patients to
receive necessary life-saving care.

Table 1. Vaccination status by race and ethnicity
Race and Ethnicity
Overall
Non-Hispanic Black
Non-Hispanic White
Non-Hispanic Asian
Hispanic

Vaccinated by
March 29,
2021 (%)

Vaccinated by
April 30,
2021 (%)

52
48
57
63
54

67
66
71
79
74

Vaccinated by
December 31,
2021 (%)
72
71
74
82
77
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Providers shared preliminary data
from their programs and created libraries
of published manuscripts from around
the world. By sharing preliminary data,
CMOs created guidance and could assess
the response of patients with ESKD to
SARS-CoV-2 vaccination.10 Providers
received guidance on the basis of data
before it was available in the United
States. Critically important data from this
collaboration assessed the response of
patients with ESKD to SARS-CoV-2 vaccination.10 Early data suggested antibody
responses to vaccination were less vigorous and took longer to develop in
patients with ESKD. In addition, antibody
production waned more quickly.
Response to the mRNA vaccines
appeared to be more potent relative to
the adenovirus vector vaccine. Consensus
among the CMOs and discussion with
the CDC led to the conclusion that third
doses are appropriate for many patients
with ESKD, particularly those who are
immunocompromised and those active
on transplant waiting lists.

ADDRESSING
CONFUSING GUIDANCE

Dialysis providers received guidance
from federal agencies (CDC, Occupational Safety and Health Administration [OSHA]), state, and local
departments of health. By sharing
interpretations, providers were better
able to manage their responses. The
lack of uniform guidance created confusion for patients who were, at times,
uncertain of how to respond to advice
from their physicians.
Late in 2021, OSHA issued guidance
for providers treating patients infected
with SARS-CoV-2 regarding required
PPE, management of exposed staff, and
ventilation of facilities. Some of this
guidance was already common practice.
Other aspects created additional burden which was eased by shared
approaches. Vaccination mandates for
health care workers, stayed in some
locations; threaten to reduce stafﬁng in
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facilities already struggling to ﬁnd sufﬁcient staff.

ADDRESSING MULTIPLE
SIMULTANEOUS CRISES

Exhausted patients and staff turned to
their CMOs for support and reassurance. Our collaboration allowed CMOs
to support and learn from each other.
Sharing data and approaches to problems created a sense that no one was
facing this crisis alone. In turn, CMOs
reassured staff that treatments,
approaches, and vaccines were emerging and that they were receiving guidance from national experts to guide
them through the pandemic.
When an ice storm hit Texas and
Tennessee in February 2021, CMOs
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Most patients arrive at dialysis centers
via ride-share services run by mass transit
companies. Transit workers risked exposure to serious illness and are another
group of unsung heroes.

CONCLUSION AND FUTURE STEPS

The COVID-19 pandemic created an
opportunity for CMOs of dialysis providers to come together to share information, data, and camaraderie in a
transparent environment. Each emerged
stronger and the entire industry
beneﬁted. Patients with ESKD gained
from the collective experience, expertise,
and knowledge.
It is not clear what challenges lie
ahead. However, the CMOs remain
committed to long-term collaboration,

Health care workers stepped up risking their own health
and that of their families to care for their patients
collaborated to ensure that water and
generators delivered to the affected
areas allowed all patients to receive
dialysis even at facilities other than
their home unit.

ONGOING CHALLENGES

When the omicron variant led to a
surge in COVID-19 cases, vaccinated
patients had milder cases. Dialysis facilities reinvigorated vaccination and
infection prevention protocols to
reduce the risks.

RECOGNIZING THE TRUE HEROES

Health care workers stepped up risking
their own health and that of their families to care for their patients.
Patients also responded to the crises,
accepting shifts in their schedules, facilities, caregivers, and treatment times without complaint.

sharing of clinical data in real time and
improving the work environment of
the dedicated professionals and patients
served in dialysis facilities across the
country. The regular calls continue
supplemented by an in-person annual
meeting once the pandemic is
controlled.
The ability to maintain the health of
patients with ESKD requires early
involvement of nephrologists in disaster
planning by hospitals and governments,
open data sharing, discussion of regulations and protocols among providers and
with governing agencies, and ongoing
discussions to ensure that guidance from
the agencies has no unintended consequences for the provision of safe care.
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